136 related articles for article (PubMed ID: 24458098)
1. Primary orthotopic glioma xenografts recapitulate infiltrative growth and isocitrate dehydrogenase I mutation.
Valadez JG; Sarangi A; Lundberg CJ; Cooper MK
J Vis Exp; 2014 Jan; (83):e50865. PubMed ID: 24458098
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
Lu VM; McDonald KL
CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
[TBL] [Abstract][Full Text] [Related]
4. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
5. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
6. An in vivo patient-derived model of endogenous IDH1-mutant glioma.
Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S
Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263
[TBL] [Abstract][Full Text] [Related]
7. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
Borodovsky A; Salmasi V; Turcan S; Fabius AW; Baia GS; Eberhart CG; Weingart JD; Gallia GL; Baylin SB; Chan TA; Riggins GJ
Oncotarget; 2013 Oct; 4(10):1737-47. PubMed ID: 24077805
[TBL] [Abstract][Full Text] [Related]
8. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
Gerardo Valadez J; Grover VK; Carter MD; Calcutt MW; Abiria SA; Lundberg CJ; Williams TV; Cooper MK
Cancer Lett; 2013 Jan; 328(2):297-306. PubMed ID: 23063752
[TBL] [Abstract][Full Text] [Related]
9. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Capper D; Sahm F; Hartmann C; Meyermann R; von Deimling A; Schittenhelm J
Am J Surg Pathol; 2010 Aug; 34(8):1199-204. PubMed ID: 20661018
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
11. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma.
Smilowitz HM; Weissenberger J; Weis J; Brown JD; O'Neill RJ; Laissue JA
J Neurosurg; 2007 Apr; 106(4):652-9. PubMed ID: 17432718
[TBL] [Abstract][Full Text] [Related]
12. The chemokine receptor CXCR7 influences prognosis in human glioma in an IDH1-dependent manner.
Birner P; Tchorbanov A; Natchev S; Tuettenberg J; Guentchev M
J Clin Pathol; 2015 Oct; 68(10):830-4. PubMed ID: 26109200
[TBL] [Abstract][Full Text] [Related]
13. Rapid Intraoperative Molecular Characterization of Glioma.
Shankar GM; Francis JM; Rinne ML; Ramkissoon SH; Huang FW; Venteicher AS; Akama-Garren EH; Kang YJ; Lelic N; Kim JC; Brown LE; Charbonneau SK; Golby AJ; Sekhar Pedamallu C; Hoang MP; Sullivan RJ; Cherniack AD; Garraway LA; Stemmer-Rachamimov A; Reardon DA; Wen PY; Brastianos PK; Curry WT; Barker FG; Hahn WC; Nahed BV; Ligon KL; Louis DN; Cahill DP; Meyerson M
JAMA Oncol; 2015 Aug; 1(5):662-7. PubMed ID: 26181761
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS hotspot mutations are rare in IDH-mutant gliomas.
Schittenhelm J; Krischker N; Gepfner-Tuma I; Behling F; Noell S; Eckert F; Biskup S; Tabatabai G
Brain Pathol; 2019 May; 29(3):321-324. PubMed ID: 30676672
[No Abstract] [Full Text] [Related]
15. IDH mutations in glioma and acute myeloid leukemia.
Dang L; Jin S; Su SM
Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
[TBL] [Abstract][Full Text] [Related]
16. Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice.
Taillandier L; Antunes L; Angioi-Duprez KS
J Neurosci Methods; 2003 May; 125(1-2):147-57. PubMed ID: 12763241
[TBL] [Abstract][Full Text] [Related]
17. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
18. Metabolism: reprogramming metabolic flux in glioma.
Lokody I
Nat Rev Cancer; 2014 Nov; 14(11):706-7. PubMed ID: 25291294
[No Abstract] [Full Text] [Related]
19. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas.
Horbinski C; Kofler J; Yeaney G; Camelo-Piragua S; Venneti S; Louis DN; Perry A; Murdoch G; Nikiforova M
Brain Pathol; 2011 Sep; 21(5):564-74. PubMed ID: 21314850
[TBL] [Abstract][Full Text] [Related]
20. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
